Altered metabolic pathways in clear cell renal cell carcinoma: A meta-analysis and validation study focused on the deregulated genes and their associated networks

Oncoscience

Volumn 1, Issue 2, 2014, Pages 117-131

  Zaravinos, Apostolos ^a   Pieri, Myrtani ^a   Mourmouras, Nikos ^b   Anastasiadou, Natassa ^c   Zouvani, Ioanna ^c   Delakas, Dimitris ^b   Deltas, Constantinos ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b IASO GENERAL HOSPITAL   (Greece)

^c NICOSIA GENERAL HOSPITAL   (Cyprus)

Author keywords

Clear cell renal cell carcinoma; Gene expression; Gene networks; Metabolic pathways; Oncomine; Pathway analysis

Indexed keywords

EID: 84898414957     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.13     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA: a cancer journal for clinicians 2009;59: 225-249.
2. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. The American journal of surgical pathology 2003;27: 612-624.
3. Rezende RB, Drachenberg CB, Kumar D, Blanchaert R, Ord RA, Ioffe OB, Papadimitriou JC: Differential diagnosis between monomorphic clear cell adenocarcinoma of salivary glands and renal (clear) cell carcinoma. The American journal of surgical pathology 1999;23: 1532-1538.
4. Hong F, Breitling R: A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments. Bioinformatics (Oxford, England) 2008;24: 374-382.
5. Boer JM, Huber WK, Sultmann H, Wilmer F, von Heydebreck A, Haas S, Korn B, Gunawan B, Vente A, Fuzesi L, Vingron M, Poustka A: Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31, 500-element cdna array. Genome research 2001;11: 1861-1870.
6. Gieseg MA, Cody T, Man MZ, Madore SJ, Rubin MA, Kaldjian EP: Expression profiling of human renal carcinomas with functional taxonomic analysis. BMC bioinformatics 2002;3: 26.
7. Higgins JP, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M, Brooks JD: Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. The American journal of pathology 2003;162: 925-932.
8. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA: Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005;11: 5730-5739.
9. Lenburg ME, Liou LS, Gerry NP, Frampton GM, Cohen HT, Christman MF: Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC cancer 2003;3: 31.
10. Sultmann H, von Heydebreck A, Huber W, Kuner R, Buness A, Vogt M, Gunawan B, Vingron M, Fuzesi L, Poustka A: Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 2005;11: 646-655.
11. Takahashi M, Sugimura J, Yang X, Vogelzang N, Teh BS, Furge K, Teh BT: Gene expression profiling of renal cell carcinoma and its implications in diagnosis, prognosis, and therapeutics. Advances in cancer research 2003;89: 157-181.
12. Yamazaki K, Sakamoto M, Ohta T, Kanai Y, Ohki M, Hirohashi S: Overexpression of kit in chromophobe renal cell carcinoma. Oncogene 2003;22: 847-852.
13. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS: Expression profiling of renal epithelial neoplasms: A method for tumor classification and discovery of diagnostic molecular markers. The American journal of pathology 2001;158: 1639-1651.
14. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM: Oncomine 3.0: Genes, pathways, and networks in a collection of 18, 000 cancer gene expression profiles. Neoplasia (New York, NY) 2007;9: 166-180.
15. White NM, Newsted DW, Masui O, Romaschin AD, Siu KW, Yousef GM: Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma. Tumour Biol. 2013.
16. Langbein S, Frederiks WM, zur Hausen A, Popa J, Lehmann J, Weiss C, Alken P, Coy JF: Metastasis is promoted by a bioenergetic switch: New targets for progressive renal cell cancer. International journal of cancer 2008;122: 2422-2428.
17. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ, Banks RE: Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the warburg effect. Proteomics 2003;3: 1620-1632.
18. Nagaprashantha LD, Talamantes T, Singhal J, Guo J, Vatsyayan R, Rauniyar N, Awasthi S, Singhal SS, Prokai L: Proteomic analysis of signaling network regulation in renal cell carcinomas with differential hypoxia-inducible factor-2alpha expression. PloS one 2013;8: e71654.
19. Maruschke M, Reuter D, Koczan D, Hakenberg OW, Thiesen HJ: Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management. BJU international 2011;108: E29-35.
20. Kiyamova R, Garifulin O, Gryshkova V, Kostianets O, Shyian M, Gout I, Filonenko V: Preliminary study of thyroid and colon cancers-associated antigens and their cognate autoantibodies as potential cancer biomarkers. Biomarkers 2012;17: 362-371.
21. Warburg O, Wind F, Negelein E: The metabolism of tumors in the body. The Journal of general physiology 1927;8: 519-530.
22. Linehan WM, Srinivasan R, Schmidt LS: The genetic basis of kidney cancer: A metabolic disease. Nature reviews 2010;7: 277-285.
23. Wu CA, Chao Y, Shiah SG, Lin WW: Nutrient deprivation induces the warburg effect through ros/ampk-dependent activation of pyruvate dehydrogenase kinase. Biochimica et biophysica acta;1833: 1147-1156.
24. San Martin A, Ceballo S, Ruminot I, Lerchundi R, Frommer WB, Barros LF: A genetically encoded fret lactate sensor and its use to detect the warburg effect in single cancer cells. PloS one 2013;8: e57712.
25. Buppajarntham S, Junpaparp P, Kue APP: Warburg effect associated with transformed lymphoplasmacytic lymphoma to diffuse large b-cell lymphoma. The American journal of emergency medicine 2013;31: 999 e995-996.
26. Poteet E, Choudhury GR, Winters A, Li W, Ryou MG, Liu R, Tang L, Ghorpade A, Wen Y, Yuan F, Keir ST, Yan H, Bigner DD, Simpkins JW, Yang SH: Reversing the warburg effect as a treatment for glioblastoma. The Journal of biological chemistry 2013;288: 9153-9164.
27. Hakimi AA, Pham CG, Hsieh JJ: A clear picture of renal cell carcinoma. Nature genetics 2013;45: 849-850.
28. Sudarshan S, Karam JA, Brugarolas J, Thompson RH, Uzzo R, Rini B, Margulis V, Patard JJ, Escudier B, Linehan WM: Metabolism of kidney cancer: From the lab to clinical practice. European urology 2013;63: 244-251.
29. Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R: Molecular diagnosis and therapy of kidney cancer. Annual review of medicine 2010;61: 329-343.
30. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, Mueller-Klieser W: Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. International journal of radiation oncology, biology, physics 2001;51: 349-353.
31. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W: High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer research 2000;60: 916-921.
32. Sandulache VC, Myers JN: Altered metabolism in head and neck squamous cell carcinoma: An opportunity for identification of novel biomarkers and drug targets. Head & neck 2012;34: 282-290.
33. Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4: 891-899.
34. Mahlknecht U, Chesney J, Hoelzer D, Bucala R: Cloning and chromosomal characterization of the 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase-3 gene (pfkfb3, ipfk2). International journal of oncology 2003;23: 883-891.
35. Moon JS, Kim HE, Koh E, Park SH, Jin WJ, Park BW, Park SW, Kim KS: Kruppel-like factor 4 (klf4) activates the transcription of the gene for the platelet isoform of phosphofructokinase (pfkp) in breast cancer. The Journal of biological chemistry 2011;286: 23808-23816.
36. Mazur L, Opydo-Chanek M, Stojak M: Glufosfamide as a new oxazaphosphorine anticancer agent. Anti-cancer drugs 2011;22: 488-493.
37. Chiorean EG, Dragovich T, Hamm J, Langmuir VK, Kroll S, Jung DT, Colowick AB, Tidmarsh GF, Loehrer PJ: A phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer chemotherapy and pharmacology 2008;61: 1019-1026.
38. Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, Tidmarsh GT: A randomised phase iii trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer 2009;45: 1589-1596.
39. Shimizu T, Okamoto I, Tamura K, Satoh T, Miyazaki M, Akashi Y, Ozaki T, Fukuoka M, Nakagawa K: Phase i clinical and pharmacokinetic study of the glucoseconjugated cytotoxic agent d-19575 (glufosfamide) in patients with solid tumors. Cancer chemotherapy and pharmacology 2010;65: 243-250.
40. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi JT, Wu J, Solow-Cordero DE, Bonnet M, Flanagan JU, Bouley DM, Graves EE, Denny WA, Hay MP, Giaccia AJ: Targeting glut1 and the warburg effect in renal cell carcinoma by chemical synthetic lethality. Science translational medicine 2011;3: 94ra70.
41. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, Sun LZ, Ahlquist DA, Wood CG, Copland JA: Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 2007;13: 4740-4749.
42. Yusenko MV, Zubakov D, Kovacs G: Gene expression profiling of chromophobe renal cell carcinomas and renal oncocytomas by affymetrix genechip using pooled and individual tumours. International journal of biological sciences 2009;5: 517-527.
43. Gagliano N, Pettinari L, Aureli M, Martinelli C, Colombo E, Costa F, Carminati R, Volpari T, Colombo G, Milzani A, Dalle-Donne I, Gioia M: Malignant phenotype of renal cell carcinoma cells is switched by ukrain administration in vitro. Anti-cancer drugs 2011;22: 749-762.
44. Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA: Identification of common differentially expressed genes in urinary bladder cancer. PloS one 2011;6: e18135.
45. Zaravinos A, Kanellou P, Baritaki S, Bonavida B, Spandidos DA: Braf and rkip are significantly decreased in cutaneous squamous cell carcinoma. Cell cycle (Georgetown, Tex) 2009;8: 1402-1408.
46. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. The American journal of surgical pathology 1982;6: 655-663.
47. Kanellou P, Zaravinos A, Zioga M, Spandidos DA: Deregulation of the tumour suppressor genes p14(arf), p15(ink4b), p16(ink4a) and p53 in basal cell carcinoma. The British journal of dermatology 2009;160: 1215-1221.
48. Zaravinos A, Soufla G, Bizakis J, Spandidos DA: Expression analysis of vegfa, fgf2, tgfbeta1, egf and igf1 in human nasal polyposis. Oncology reports 2008;19: 385-391.
49. Zaravinos A, Chatziioannou M, Lambrou GI, Boulalas I, Delakas D, Spandidos DA: Implication of raf and rkip genes in urinary bladder cancer. Pathol Oncol Res 2011;17: 181-190.
50. Pepe MS, Thompson ML: Combining diagnostic test results to increase accuracy. Biostatistics (Oxford, England) 2000;1: 123-140.
51. Zhang B, Kirov S, Snoddy J: Webgestalt: An integrated system for exploring gene sets in various biological contexts. Nucleic acids research 2005;33: W741-748.